HC Wainwright & Co. Reiterates Buy Rating on 4D Molecular Therapeutics, Inc. Common Stock (FDMT)

Market Context

4D Molecular Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $11.09 with a market capitalization of $510.5M. The stock has gained 158.0% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for 4D Molecular Therapeutics, Inc. Common Stock.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for 4D Molecular Therapeutics, Inc. Common Stock

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 20, 2026	HC Wainwright & Co.	Buy	N/A
Mar 20, 2026	HC Wainwright & Co.	Buy	N/A
Mar 19, 2026	RBC Capital	Outperform	N/A
Mar 19, 2026	Chardan Capital	Buy	N/A
Jan 28, 2026	Barclays	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View FDMT Stock Page